Comparing two chemotherapies for bile duct cancer that returns after surgery
Treatments studied
Part of Cancer clinical trials.
This trial compares two types of chemotherapy for people whose bile duct cancer has come back after surgery. It tests if a combination of irinotecan liposomes, 5-FU, and leucovorin works better than the standard pill capecitabine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your bile duct cancer was completely removed by surgery, but it came back.
- You had at least one risk factor like cancer in lymph nodes or blood vessels.
- You have not had chemotherapy before for this cancer.
- You are in generally good health and can take care of yourself (ECOG 0 or 1).
- Your liver and kidney function are good enough to handle the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (irinotecan liposome, capecitabine, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has worsened after one prior treatment. It may be an option if you haven't taken capecitabine or lenvatinib before and are generally feeling well.
This study tests whether giving chemotherapy directly into the liver (HAIC) plus an oral chemo pill (capecitabine) after surgery helps prevent bile duct cancer from coming back, compared to just the pill. It's for people who recently had their cancer completely removed.
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
This trial tests a specific chemotherapy after surgery for people with stage II or III bile duct, gallbladder, or ampullary cancer. It may help reduce the chance of cancer coming back.
This trial tests if a combination of immunotherapy (durvalumab), chemotherapy (GEMOX or GC), and a targeted therapy (lenvatinib) works better than standard capecitabine chemotherapy to prevent cancer from coming back after surgery for bile duct or gallbladder cancer.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Hear when a new Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.